These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9748054)

  • 21. [Zolmitriptan].
    Le Jeunne C
    Presse Med; 1999 Sep; 28(28):1525-6. PubMed ID: 10526561
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of the antimigraine compound zolmitriptan ('Zomig') on psychomotor performance alone and in combination with diazepam in healthy volunteers.
    Dixon R; Hughes AM; Nairn K; Sellers M; Kemp JV; Yates RA
    Cephalalgia; 1998 Sep; 18(7):468-75. PubMed ID: 9793699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers.
    Seaber EJ; Peck RW; Smith DA; Allanson J; Hefting NR; van Lier JJ; Sollie FA; Wemer J; Jonkman JH
    Br J Clin Pharmacol; 1998 Nov; 46(5):433-9. PubMed ID: 9833595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Vigabatrin on motor responses to transcranial magnetic stimulation: an effective tool to investigate in vivo GABAergic cortical inhibition in humans.
    Pierantozzi M; Marciani MG; Palmieri MG; Brusa L; Galati S; Caramia MD; Bernardi G; Stanzione P
    Brain Res; 2004 Nov; 1028(1):1-8. PubMed ID: 15518635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. International clinical experience based on > 3000 subjects treated with zolmitriptan.
    Edmeads JG; Millson DS
    Cephalalgia; 1997 Oct; 17 Suppl 18():41-52. PubMed ID: 9399016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Zolmitriptan].
    Monseu G; Sternon J
    Rev Med Brux; 1998 Dec; 19(6):495-9. PubMed ID: 9916496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women.
    Peck RW; Seaber EJ; Dixon RM; Layton GR; Weatherley BC; Jackson SH; Rolan PE; Posner J
    Clin Pharmacol Ther; 1998 Mar; 63(3):342-53. PubMed ID: 9542478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measuring event-related potentials.
    Dixon R
    Cephalalgia; 1999 Jul; 19 Suppl 24():29-30; discussion 30-1. PubMed ID: 10526680
    [No Abstract]   [Full Text] [Related]  

  • 29. The novel anti-migraine compound zolmitriptan (Zomig 311C90) has no clinically significant interactions with paracetamol or metoclopramide.
    Seaber EJ; Ridout G; Layton G; Posner J; Peck RW
    Eur J Clin Pharmacol; 1997; 53(3-4):229-34. PubMed ID: 9476036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Auditory evoked potentials in the assessment of central nervous system effects of antimigraine drugs.
    Roon KI; Sándor PS; Schoonman GG; Lamers FP; Schoenen J; Ferrari MD; van Dijk JG
    Cephalalgia; 1999 Dec; 19(10):880-5. PubMed ID: 10668107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90).
    Rolan P
    Cephalalgia; 1997 Oct; 17 Suppl 18():21-7. PubMed ID: 9399014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of 5HT in migraine.
    Buzzi MG
    Cephalalgia; 1999 Sep; 19(7):625-6. PubMed ID: 10524654
    [No Abstract]   [Full Text] [Related]  

  • 33. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90).
    Seaber E; On N; Dixon RM; Gibbens M; Leavens WJ; Liptrot J; Chittick G; Posner J; Rolan PE; Pack RW
    Br J Clin Pharmacol; 1997 Jun; 43(6):579-87. PubMed ID: 9205817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low dose zolmitriptan as a 5-HT neuroendocrine challenge agent in humans.
    Moeller FG; Bjork JM; Dougherty DM; Van de Kar LD; Marsh DM; Swann AC
    Psychoneuroendocrinology; 2000 Aug; 25(6):607-18. PubMed ID: 10840172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Valeriana officinalis Root Extract Modulates Cortical Excitatory Circuits in Humans.
    Mineo L; Concerto C; Patel D; Mayorga T; Paula M; Chusid E; Aguglia E; Battaglia F
    Neuropsychobiology; 2017; 75(1):46-51. PubMed ID: 29035887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of hepatic impairment on the pharmacokinetics of zolmitriptan.
    Dixon R; French S; Kemp J; Sellers M; Leclerc V; Delvaux M; Rautureau J
    J Clin Pharmacol; 1998 Aug; 38(8):694-701. PubMed ID: 9725544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancement of human motor cortex inhibition by the dopamine receptor agonist pergolide: evidence from transcranial magnetic stimulation.
    Ziemann U; Bruns D; Paulus W
    Neurosci Lett; 1996 Apr; 208(3):187-90. PubMed ID: 8733301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The excitability of human cortical inhibitory circuits responsible for the muscle silent period after transcranial brain stimulation.
    Bertasi V; Bertolasi L; Frasson E; Priori A
    Exp Brain Res; 2000 Jun; 132(3):384-9. PubMed ID: 10883387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy.
    Schoenen J; Sawyer J
    Cephalalgia; 1997 Oct; 17 Suppl 18():28-40. PubMed ID: 9399015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical pharmacokinetics of zolmitriptan.
    Dixon R; Warrander A
    Cephalalgia; 1997 Oct; 17 Suppl 18():15-20. PubMed ID: 9399013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.